SCRS Expands Relationship with Acurian
The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing the interests of clinical research sites, announced an expanded relationship with Acurian Inc., a full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD.
The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing the interests of clinical research sites, announced an expanded relationship with Acurian Inc., a full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD.
In this expansion, Acurian support an increased number of member programs. These include the initiation of a Site Advocacy Group (SAG) focused on global patient recruitment and sponsor both the 2015 SCRS Eagle Award and Site Patient Recruitment Innovation Award (SPRIA). Acurian also will continue as a Global Impact Partner and sponsor of 2015 Good Business Practices and Good Clinical Practices webinars.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
